VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting
Vaccine Information
  • Vaccine Name: M. tuberculosis DNA Vaccine APADNA priming and APAMVA boosting
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0011478
  • Type: Other
  • Status: Research
  • Apa gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pUMVC3 DNA vaccine plasmid
  • Immunization Route: Intradermal injection (i.d.)
Host Response

Guinea pig Response

  • Vaccination Protocol: Animals were immunized intradermally with APADNA, 200 μg, given three times, 4 weeks apart (at weeks 0, 4, and 8), followed by APAMVA, 107 PFU, given 4 weeks after the third DNA (at 12 weeks); or BCG Guindy, 106 CFU, given one time only (at week 0) or control DNA, 200 μg, given three times, 4 weeks apart (at weeks 0, 4, and 8), followed by MVA wild type, 107 PFU, given 4 weeks after the third DNA (at week 12) (Kumar et al., 2003).
  • Challenge Protocol: Animals were challenged intramuscularly in the thigh muscle at 4 weeks after the last immunization with 2 × 105 viable M. tuberculosis strain NTI64719. This challenge dose was sufficient to cause measurable clinical illness in all control animals within a relatively short time frame of 6 weeks (Kumar et al., 2003).
  • Efficacy: A poxvirus recombinant expressing the Apa protein conferred a significant level of protective immunity in guinea pigs against a challenge dose of virulent M. tuberculosis (Kumar et al., 2003).
References
Kumar et al., 2003: Kumar P, Amara RR, Challu VK, Chadda VK, Satchidanandam V. The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4+ and CD8+ T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model. Infection and immunity. 2003; 71(4); 1929-1937. [PubMed: 12654810].